Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report

Yan Zhang1
Bixiu He2
Dongbo Zhou2
Min Li1
Chengping Hu1

1Department of Respiratory Medicine, Xiangya Hospital (Key Cite of National Clinical Research Center for Respiratory Disease), Central South University, Changsha, Hunan, P.R. China; 2Department of Gerontology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China

Background: T790M mutation is well known as the most common mechanism for resistance to the first- and second-generation tyrosine kinase inhibitors (TKIs) for EGFR mutation in non-small-cell lung cancer. Several third-generation EGFR TKIs, such as osimertinib, have been explored and approved for conquering this resistance; however, acquired resistance to osimertinib is evident and the resistance mechanisms remain complex and incompletely explored.

Case presentation: A non-smoking 58-year-old female patient was initially diagnosed with lung adenocarcinoma harboring EGFR exon 19 deletion and clinically responded to initial gefitinib treatment. The patient progressed on gefitinib after 1 year and a T790M mutation was detected in tissue biopsy by next-generation sequencing (NGS). Osimertinib treatment was administrated for several months and an acquired rare EGFR G724S mutation was detected via NGS blood sample after osimertinib resistance.

Conclusion: The specific mechanisms of acquiring drug resistance for EGFR-TKIs have not been fully explored. EGFR G724S mutation might be associated with osimertinib resistance but more studies about the mechanism should be explored.

Keywords: NSCLC, EGFR mutation, tyrosine kinase inhibitor, next-generation sequencing

Background
EGFR gene mutations in lung adenocarcinoma are closely related to the clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs). Commonly used EGFR-TKIs include gefitinib, erlotinib (and icotinib) as the first-generation EGFR-TKIs, and afatinib (and dacomitinib) as the second generation, and osimertinib as the third generation. Furthermore, many clinical trials have demonstrated that EGFR-TKIs significantly increased clinical benefits compared with the standard chemotherapies in non-small-cell lung cancer (NSCLC) patients. However, most NSCLC patients eventually developed resistance to these first-generation TKIs within 1 year. The EGFR exon 20 T790M mutation has been well known as the major resistant mutation for the first- and second-generation TKIs. Approximately 50% of the patients with TKI resistance were detected of harboring the EGFR T790M mutation. Several third-generation EGFR-mutant selective TKIs, such as osimertinib (AZD9291), olmutinib (HM61713), and rociletinib, are being developed for EGFR T790M mutation in NSCLC. Osimertinib targets both sensitive EGFR mutation and resistant T790M, and a better benefit of progression-free survival (PFS) was observed in osimertinib (mPFS 18.9 months).
when compared to a standard first-generation EGFR-TKI (gefitinib or erlotinib, 10.2 months).\(^3\) Even so, most patients who were given the third-generation EGFR-TKIs would eventually develop resistance after several months. Acquired resistant C797S mutation, also located in EGFR exon 20, has been reported as one of the most important resistance mechanisms of osimertinib,\(^6,7\) and C797S mutation was also reported as acquired resistance to another T790M-specific third-generation EGFR-TKI (HM61713) in NSCLC.\(^8\) Other mechanisms of resistance to osimertinib are reported, such as MET and HER2 amplification and small-cell lung cancer transformation.\(^5,9\) EGFR L718Q has also been found in T790M-positive patients after osimertinib resistance.\(^9\) Here, we report an extremely rare and complicated acquired mutation of EGFR exon 18 G724S after osimertinib resistance.

**Case presentation**

A non-smoking 58-year-old female was diagnosed with lung adenocarcinoma (pT2N0M0, according to seventh TNM classification) after right lower lobe lobectomy. A SurPlex™ liquid chip test (SurPlex™-xTAG, Surexam, P.R. China) was performed on the resected tumor tissue, which showed an activated mutation of EGFR exon 19 deletion (19 Del, p.E746_S752>V), no KRAS, BRAF, PIK3CA mutation. The patient was administered with gefitinib at a dose of 250 mg/day for 1 year, during which the patient was stable (according to the Response Evaluation Criteria in Solid Tumors). Gefitinib therapy was discontinued after appearance of liver metastasis in December 2013, and second-line chemotherapy (pemetrexed 850 mg, d1–d3) and percutaneous microwave coagulation therapy of liver were administrated. However, the patient discontinued the chemotherapy after two cycles due to serious adverse effects of nausea and vomiting and continued with gefitinib treatment again. New liver metastases and a pulmonary mass were detected in March 2015. Wedge resection of left upper lobe was carried out by video-assisted thoracoscopic surgery and pathological diagnosis was adenocarcinoma (pT2NxM1, IV stage). Next-generation sequencing (NGS, Langqing™, Burning Rock Dx, P.R. China) of the tumor biopsy presented EGFR 19 Del and T790M mutation, MAP2K1 and TP53 mutation, no ALK and ROS1 mutation. The patient was enrolled in the Phase II clinical trial of osimertinib (40 mg/day) instead of gefitinib therapy. The patient progressed with brain metastasis in June 2015 and withdrew from the clinical trial and changed dose of osimertinib from 40 mg/day to standard 80 mg/day, complementary with stereotactic brain irradiation. The patient developed multiple metastases after several months and the peripheral blood NGS test (Langqing™) showed rare EGFR G724S on 2 June 2016 (in addition to EGFR 19 Del and T790M). Then, the therapy combined osimertinib 80 mg/day and gefitinib 250 mg/day. Moreover, the patient’s family purchased pembrolizumab and cabozantinib (XL184) from outside China, which also failed to slow down the progress of the disease. Two additional peripheral blood NGS tests revealed MET amplification in August and September 2016. However, the disease worsened quickly and the patient died of respiratory failure on 25 September 2016. All the processes of diagnosis and treatment are shown below (Figure 1 and Table 1).

**Discussion**

T790M mutation is well known as the most common resistant mutation for the first- and second-generation TKIs for EGFR mutation.\(^11\) Osimertinib as a selective third-generation TKI has been explored and approved for treating EGFR T790M in NSCLC patients. A better clinical response was also observed in osimertinib group compared to gefitinib and/or erlotinib group in untreated EGFR-mutant advanced NSCLC.\(^5\) However, similar to patients treated with first- or second-generation EGFR TKIs, resistance eventually occurred in patients treated with osimertinib after no >10 months.\(^12\) Several mechanisms of resistance including EGFR-dependent and EGFR-independent were reported. EGFR exon 20 C797S was reported to be a major resistance mechanism to osimertinib as an EGFR-dependent mechanism.\(^8,13,14\) EGFR C797S codon, located in the kinase-binding pocket, results in loss of binding of osimertinib to EGFR. Similarly, C797S has also been detected in EGFR T790M patients with rociletinib, olmutinib, and nazartinib treatment.\(^8,15,16\) However, there are still numerous patients who have acquired resistance to these third-generation TKIs without acquiring C797S mutation.\(^13\) More recently, a novel EGFR C797G mutation has been reported after osimertinib resistance.\(^17\) Other rare EGFR mutations, including G796S/R, L792F/H, L798I, and L718Q, have also been reported to be possible resistance mutations to osimertinib.\(^10,18–20\) EGFR T790M loss was often seen early after osimertinib treatment and was accompanied by osimertinib resistance in a shorter time compared to those with maintained T790M.\(^21\) EGFR-independent mechanisms have been reported in tumor or plasma samples, including MET and HER-2 amplification,\(^22\) MAPK activation,\(^23\) mutations in KRAS,\(^15\) PI3KCA,\(^16\) BRAF,\(^24\) and transformation to small-cell lung cancer.\(^25\)

Herein, we report that EGFR exon 18 G724S may serve as an acquired potential resistance mutation in a
Newly emergent acquired EGFR exon 18 G724S mutation after resistance

Table 1

| Gene    | Exon | Amino acid | Nucleotide               | December 2012 (tumor tissue: SurPlex™ liquid chip test) | AF%, April 2015 (left lung mass: NGS) | AF%, June 2016 (peripheral blood: NGS) | AF%, August 2016 (peripheral blood: NGS) | AF%, September 2016 (peripheral blood: NGS) |
|---------|------|------------|--------------------------|--------------------------------------------------------|---------------------------------------|------------------------------------------|------------------------------------------|---------------------------------------------|
| EGFR    | 19   | 2237-2255del AATTAA GAGAAGCAACATCinsT | Exon 19 del (p.E746-S752>V) | 15.2 | 5.33 | 7.97 | 15.6 |
|         | 20   | T790M      | 2369C>T                  | 11.5 | 1.34 | 5.37 | 8.42 |
|         | 18   | G724S      | 2170G>A                  | 1.56 | 0.89 | 0.97 | 0.97 |
| MAP2K1 (MEK1) | 2   | D67E       | 201C>G                   | 16.1 | 2.88 | 11.9 | 21.8 |
| TP53    |      | c.764-766del | c.764-766del | 13.4 | 20.42 | 10.6 | 3.33 |
| MET     |      | CN =2.46   | CN =3.01                |                                          |                                        |                                          |                                          |

Abbreviations: AF, allelic frequency; NGS, next-generation sequencing.
Table 2: General clinical characteristics of patients harboring the EGFR G724S mutation after TKIs treatment

| Case      | Sex/age | Smoking status | Stage | Firstly detected EGFR mutation/TKIs | Secondly detected EGFR mutation/TKIs | Thirdly detected EGFR mutation | G724S (MAF) |
|-----------|---------|----------------|-------|-------------------------------------|-------------------------------------|-------------------------------|-------------|
| Our case  | F/58    | Never          | II→IV | Exon 19 Del/gefitinib               | T790M/osimertinib                   | G724S                    | 1.56/0.89/0.97 |
| Oztan26   | F/47    | _              | IV    | Exon 19 Del/erlotinib→afatinib      | T790M/osimertinib                   | G724S                    | 5%          |
| Oztan26   | M/74    | _              | IV    | Exon 19 Del/erlotinib/→osimertinib  | G724S                              | 0.7%                      |
| Peled27   | F/49    | Never          | IIIA  | Exon 19 Del/gefitinib               | T790M/G724S                        | _                          | 2.9%        |
| Li28      | _       | _              | _     | Exon 19 Del/gefitinib or erlotinib  | T790M/G724S                        | _                          | 10.1%       |
| Li28      | _       | _              | _     | Exon 19 Del/gefitinib or erlotinib  | _                                   | G724S                     | 1.4%        |
| Li28      | _       | _              | _     | Exon 19 Del/gefitinib or erlotinib  | _                                   | G724S                     | 80.5%       |
| Li28      | _       | _              | _     | Exon 19 Del/gefitinib or erlotinib  | _                                   | G724S                     | 37.9%       |
| Li28      | _       | _              | _     | Exon 19 Del/gefitinib or erlotinib  | _                                   | G724S                     | 59.9%       |
| Fassunke29 | F/59    | _              | IIIA  | _/erlotinib                        | T790M/osimertinib                   | G724S                    | 6.3%        |
| Fassunke29 | F/47    | _              | IV    | _/erlotinib                        | T790M/EGF816                       | G724S                     | 71.1%       |
| Fassunke29 | F/68    | _              | IV    | _/gefitinib                        | T790M/G724S/osimertinib            | _                          | 5.3%/49.6%  |
| Fassunke29 |_/69    | _              | IV    | _/erlotinib                        | T790M/G724S/osimertinib            | _                          |_/39.3%     |

Abbreviations: TKIs, tyrosine kinase inhibitors; F, female; M, male; MAF, mutant allele frequency; _, not mentioned.

In conclusion, we should make best use of the highly advanced tools for lung cancer, like ctDNA and NGS, to discover therapeutic benefits of drugs and variations of the diseases. EGFR G724S has been reported to show potential resistance to osimertinib, but more studies should be performed to explore the mechanisms conferred by this mutation in regards to osimertinib resistance.

Ethics approval and consent to participate

Research reported in the study was approved by Review Board of Xiangya Hospital, Central South University.
**Consent for publication**
Documented written consent from the patient was obtained to report the details of the case.

**Data sharing statement**
All data generated or analyzed during this study are included in this published article.

**Acknowledgments**
The authors thank Abira Afzal Choudhry and Heather Chen for helping to polish the language. We greatly appreciate the patient and her family for their kind cooperation. The present study was supported by grants from the Central South University Innovation Foundation for Postgraduates (#2017zzts209).

**Author contributions**
All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**Disclosure**
The authors report no conflicts of interest in this work.

**References**
1. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 2012;13(3):239–246.
2. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. *J Clin Oncol.* 2005;23(28):6829–6837.
3. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med.* 2005;352(8):786–792.
4. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. *Clin Cancer Res.* 2006;12(19):5764–5769.
5. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med.* 2018; 378(2):113–125.
6. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. *N Engl J Med.* 2015;372(18):1689–1699.
7. Yu HA, Tian SK, Drilon AE, et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. *JAMA Oncol.* 2015;1(7):982–984.
8. Song HN, Jung KS, Yoo KH, et al. Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small-cell lung cancer. *J Thorac Oncol.* 2016;11(4):e45–e47.
9. Wu YL, Ahn MJ, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: Data from a randomized phase III trial (AURA3). *J Clin Oncol.* 2018;36(26):2702–2709.
10. Bersanelli M, Minari R, Bordi P, et al. L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC. *J Thorac Oncol.* 2016;11(10):e121–e123.
11. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. *Nat Rev Cancer.* 2007;7(3):169–181.
12. Costa DB, Kobayashi SS. Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. *Transl Lung Cancer Res.* 2015;4(6):809–815.
13. Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. *Nat Med.* 2015;21(6):560–562.
14. Niederst MJ, Hu H, Mulvey HE, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. *Clin Cancer Res.* 2015;21(17):3924–3933.
15. Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. *Nat Commun.* 2016;7(1):11815.
16. Tan DSW, Kim DW, Leigh NB, et al. Genomic profiling of resistant tumor samples following progression on EGFR186, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer. 2017 ASCO Annual Meeting. *J Clin Oncol.* 2017;35(15_suppl):11506–11506.
17. Menon R, Müller J, Schneider P, et al. A novel EGFR (C797) variant detected in a pleural biopsy specimen from an osimertinib-treated patient using a comprehensive hybrid capture-based next-generation sequencing assay. *J Thorac Oncol.* 2016;11(9):e105–e107.
18. Chen K, Zhou F, Shen W, et al. Novel mutations on EGFR L8592 potentially correlate to acquired resistance to osimertinib in advanced NSCLC. *J Thorac Oncol.* 2017;12(6):e65–e68.
19. Yang Z, Yang N, Ou Q, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. *Clin Cancer Res.* 2018;24(13):3097–3107.
20. Ou SI, Cui J, Schrock AB, et al. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796R/S) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. *Lung Cancer.* 2017;108:228–231.
21. Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. *JAMA Oncol.* 2018;4(11):1527–1534.
22. Planchard D, Loriot Y, André F, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. *Ann Oncol.* 2015;26(10):2073–2078.
23. Kim TM, Song A, Kim DW, et al. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor. *J Thorac Oncol.* 2015;10(12):1736–1744.
24. Ho CC, Liao WY, Lin CA, Shih JY, Yu CJ, Chih-Hsin Yang J. Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib. *J Thorac Oncol.* 2017;12(3):567–572.
25. Ham JS, Kim S, Kim HK, et al. Two cases of small cell lung cancer harboring EGFR T790M. *J Thorac Oncol.* 2017;12(5):776–778.
26. Ham JS, Kim S, Kim HK, et al. Two cases of small cell lung cancer harboring EGFR T790M. *J Thorac Oncol.* 2017;12(5):776–778.
29. Fassunke J, Müller F, Keul M, et al. Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. *Nat Commun*. 2018;9(1):4655.

30. ManChon U, Talevich E, Katiyar S, Rasheed K, Kannan N. Prediction and prioritization of rare oncogenic mutations in the cancer Kinome using novel features and multiple classifiers. *PLoS Comput Biol*. 2014;10(4):e1003545.